Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations | Synapse
September 16, 2024
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.